Title : Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.

Pub. Date : 2022 Mar

PMID : 35294730






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The benefit of more potent P2Y12 inhibitors such as ticagrelor or prasugrel in stable patients is unproven, but their use might be reasonable in those with high clinical or angiographic features of increased ischemic risk without increased risk of bleeding. Prasugrel Hydrochloride purinergic receptor P2Y12 Homo sapiens